GOLGA6L6

Across TCGA pan-cancer cohorts, GOLGA6L6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GOLGA6L6 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GOLGA6L6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6L6 expression acts as an unfavorable survival marker.

OV, ESCA, and TGCT are the cancer types where GOLGA6L6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	III,IV	0.022	0.837	<.001	24	view →
ESCA	OS	Median	IV	0.095	0.512	.008	12	view →
TGCT	DFS	Median	All	0.174	0.801	.041	6	view →
CESC	OS	Median	All	0.538	0.800	.033	6	view →
LIHC	DFS	Median	All	0.167	0.555	.039	6	view →
COAD	OS	Median	All	0.312	0.806	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GOLGA6L6–OV (OS)

Open the OV breakdown →